AR033378A1 - DERIVATIVE OF ANTIGEN OF PROSTASE, NUCLEIC ACID SEQUENCE THAT CODIFIES IT, VECTOR OF EXPRESSION CONTAINING THE PREVIOUS, CELLULATED BONE TRANSFORMED WITH SUCH SEQUENCE OF A NUCLEIC ACID OR SUCH VECTOR, VACCINE THAT UNDERSTANDS THE NUMBER OF DERIVATIVE OF NUT USE OF - Google Patents
DERIVATIVE OF ANTIGEN OF PROSTASE, NUCLEIC ACID SEQUENCE THAT CODIFIES IT, VECTOR OF EXPRESSION CONTAINING THE PREVIOUS, CELLULATED BONE TRANSFORMED WITH SUCH SEQUENCE OF A NUCLEIC ACID OR SUCH VECTOR, VACCINE THAT UNDERSTANDS THE NUMBER OF DERIVATIVE OF NUT USE OFInfo
- Publication number
- AR033378A1 AR033378A1 ARP010103045A ARP010103045A AR033378A1 AR 033378 A1 AR033378 A1 AR 033378A1 AR P010103045 A ARP010103045 A AR P010103045A AR P010103045 A ARP010103045 A AR P010103045A AR 033378 A1 AR033378 A1 AR 033378A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- nucleic acid
- prostase
- vaccines
- sequence
- Prior art date
Links
- 150000007523 nucleic acids Chemical group 0.000 title abstract 8
- 102100034872 Kallikrein-4 Human genes 0.000 title abstract 6
- 108010024383 kallikrein 4 Proteins 0.000 title abstract 6
- 229960005486 vaccine Drugs 0.000 title abstract 6
- 108091028043 Nucleic acid sequence Proteins 0.000 title abstract 4
- 239000000427 antigen Substances 0.000 title abstract 4
- 102000036639 antigens Human genes 0.000 title abstract 4
- 108091007433 antigens Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 title abstract 4
- 108020004707 nucleic acids Proteins 0.000 title abstract 4
- 239000013598 vector Substances 0.000 title abstract 3
- 210000000988 bone and bone Anatomy 0.000 title 1
- 235000018102 proteins Nutrition 0.000 abstract 8
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 108090000623 proteins and genes Proteins 0.000 abstract 8
- 230000004927 fusion Effects 0.000 abstract 5
- 239000002671 adjuvant Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 239000004698 Polyethylene Substances 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000002170 ethers Chemical class 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000007764 o/w emulsion Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- -1 polyethylene Polymers 0.000 abstract 1
- 229920000573 polyethylene Polymers 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 239000007762 w/o emulsion Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describen y reivindican derivados de antígeno de la prostasa, donde la secuencia de la prostasa tiene una mutacion en el sitio activo de la proteína. Preferentemente, en el sitio activo se introduce una mutacion histidina ------ Alanina. La proteína prostasa mutada puede asociarse por fusion con una molécula, por ejemplo, por fusion con una molécula de fusion inmunologica por fusion con una molécula que potencia la expresion. Por ejemplo, la molécula en fusion, es la proteína NS1 procedente de la influenza o un fragmento de la misma. El antígeno puede comprender restos tiol modificados, los cuales pueden estar carboxiamidados o carboximetilados. La proteína puede comprender además senales de afinidad; una secuencia de ácidos nucleicos que codifican una proteína como la que se describe; un vector de expresion que contiene dicho ácido nucleico; células huéspedes que están transformadas con una secuencia del ácido nucleico o con dicho vector. Vacunas que contienen esa proteína o dicho ácido nucleico. Las vacunas pueden comprender además adyuvantes y/o citoquinas o quimioquinas inmunoestimulantes. Los adyuvantes pueden comprender uno o más de 3D-MPL, QS21, oligonucleotidos con CpG o éteres o ésteres de polietileno y la proteína preferentemente se incluye en una emulsion de agua en aceite o en una emulsion de aceite en agua como vehículo. Las vacunas pueden comprender además uno o más antígenos distintos. El uso de la proteína o del ácido nucleico comprende la fabricacion de vacunas para tratar inmunoterapéuticamentea pacientes que sufren cáncer de prostata u otros tumores asociados con la prostasa y el procedimiento para la produccion de la proteína que comprende transformar células huéspedes con la secuencia del ácido nucleico, expresar dicha secuencia y aislar el producto deseado. A su vez, el procedimiento para la produccion de vacunas que comprende las etapas de purificar la proteína prostasa (o derivados de la misma) por el procedimiento anterior , y mezclar la proteína resultante con adyuvantes, diluyentes u otros excipientes farmacéuticamente aceptables y apropiados.Prostase antigen derivatives are described and claimed, where the prostase sequence has a mutation at the active site of the protein. Preferably, a histidine mutation ------ Alanine is introduced into the active site. The mutated prostase protein can be associated by fusion with a molecule, for example, by fusion with an immunological fusion molecule by fusion with a molecule that enhances expression. For example, the fusion molecule is the NS1 protein from influenza or a fragment thereof. The antigen may comprise modified thiol moieties, which may be carboxyamidated or carboxymethylated. The protein may further comprise affinity signals; a nucleic acid sequence encoding a protein as described; an expression vector containing said nucleic acid; host cells that are transformed with a nucleic acid sequence or with said vector. Vaccines that contain that protein or said nucleic acid. Vaccines may also comprise adjuvants and / or cytokines or immunostimulatory chemokines. The adjuvants may comprise one or more of 3D-MPL, QS21, oligonucleotides with CpG or polyethylene ethers or esters and the protein is preferably included in a water-in-oil emulsion or an oil-in-water emulsion as a vehicle. Vaccines may also comprise one or more different antigens. The use of the protein or nucleic acid comprises the manufacture of vaccines to immunotherapeutically treat patients suffering from prostate cancer or other tumors associated with prostase and the method for the production of the protein comprising transforming host cells with the nucleic acid sequence. , express said sequence and isolate the desired product. In turn, the process for the production of vaccines comprising the steps of purifying the prostase protein (or derivatives thereof) by the above procedure, and mixing the resulting protein with adjuvants, diluents or other pharmaceutically acceptable and appropriate excipients.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0015736.2A GB0015736D0 (en) | 2000-06-27 | 2000-06-27 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033378A1 true AR033378A1 (en) | 2003-12-17 |
Family
ID=9894505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103045A AR033378A1 (en) | 2000-06-27 | 2001-06-26 | DERIVATIVE OF ANTIGEN OF PROSTASE, NUCLEIC ACID SEQUENCE THAT CODIFIES IT, VECTOR OF EXPRESSION CONTAINING THE PREVIOUS, CELLULATED BONE TRANSFORMED WITH SUCH SEQUENCE OF A NUCLEIC ACID OR SUCH VECTOR, VACCINE THAT UNDERSTANDS THE NUMBER OF DERIVATIVE OF NUT USE OF |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR033378A1 (en) |
| AU (1) | AU2001285773A1 (en) |
| GB (1) | GB0015736D0 (en) |
| WO (1) | WO2002000708A2 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5786148A (en) * | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
| US5955306A (en) * | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
| DE19805633A1 (en) * | 1998-02-12 | 1999-08-19 | Basf Ag | New prostate serine protease |
| CA2334038A1 (en) * | 1998-07-14 | 2000-01-27 | Corixa Corporation | Compositions and methods for therapy and diagnosis of prostate cancer |
| CA2378846A1 (en) * | 1999-07-13 | 2001-01-18 | Smithkline Beecham Biologicals S.A. | Prostase vaccine |
-
2000
- 2000-06-27 GB GBGB0015736.2A patent/GB0015736D0/en not_active Ceased
-
2001
- 2001-06-21 WO PCT/EP2001/007079 patent/WO2002000708A2/en active Application Filing
- 2001-06-21 AU AU2001285773A patent/AU2001285773A1/en not_active Abandoned
- 2001-06-26 AR ARP010103045A patent/AR033378A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002000708A3 (en) | 2002-05-16 |
| GB0015736D0 (en) | 2000-08-16 |
| AU2001285773A1 (en) | 2002-01-08 |
| WO2002000708A2 (en) | 2002-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11761009B2 (en) | Artificial nucleic acid molecules for improved protein expression | |
| US10047375B2 (en) | Artificial nucleic acid molecules | |
| CA2927254C (en) | Artificial nucleic acid molecules | |
| KR102075581B1 (en) | Adjuvant comprising nucleic acid molecule inserted viral expression regulation sequence and phamraceutical composition having the adjuvant | |
| Tan et al. | Optimization of an mRNA vaccine assisted with cyclodextrin-polyethyleneimine conjugates | |
| Van Lint et al. | The ReNAissanCe of mRNA-based cancer therapy | |
| ES2890023T3 (en) | Alphavirus particles and preparation methods | |
| BR112021024786A2 (en) | RNA construct, nucleic acid sequence, expression cassette, recombinant vector, pharmaceutical composition, method for preparing the RNA construct, vaccine, method for modifying a cell ex vivo or in vitro and modified cell | |
| US20190032077A1 (en) | Artificial nucleic acid molecules | |
| BRPI0412202A (en) | immunization patch having a microprojection array, and method | |
| EA200100425A1 (en) | NEW METHODS OF THERAPEUTIC VACCINATION | |
| CL2019003407A1 (en) | Isolated tumor associated peptide (tumap); nucleic acid; expression vector; recombinant host cell comprising the peptide; method of producing the peptide; use to prepare a rare useful drug to treat cancer; pharmaceutical kit. (divisional request 201702407) | |
| AU2019321186B2 (en) | Immunogenic compositions and uses thereof | |
| CO5580165A1 (en) | MODIFIED ROTAVIRUS VACCINES | |
| US10472647B2 (en) | Primary mesenchymal stem cells as a vaccine platform | |
| DE60229659D1 (en) | ANTIGEN RASTER CONTAINS RANKL FOR THE TREATMENT OF BONE DISEASES | |
| AR039846A1 (en) | NUCLEIC ACID MOLECULA CODIFYING AN OLD MUC-1, SUCH MOLECULA BEING ABLE TO PRODUCE AN IMMUNE RESPONSE IN VIVO | |
| DK0889969T3 (en) | Recombinant adenoviral for gene therapy of human tumors | |
| AR033378A1 (en) | DERIVATIVE OF ANTIGEN OF PROSTASE, NUCLEIC ACID SEQUENCE THAT CODIFIES IT, VECTOR OF EXPRESSION CONTAINING THE PREVIOUS, CELLULATED BONE TRANSFORMED WITH SUCH SEQUENCE OF A NUCLEIC ACID OR SUCH VECTOR, VACCINE THAT UNDERSTANDS THE NUMBER OF DERIVATIVE OF NUT USE OF | |
| Ankrah et al. | Clinical Analysis and Applications of mRNA Vaccines in Infectious Diseases and Cancer Treatment | |
| Kreiter et al. | FLT3 ligand as a molecular adjuvant for naked RNA vaccines | |
| EP3842537A1 (en) | Artificial nucleic acid molecules | |
| Hadi et al. | Development of Delivery Systems Enhances the Potency of Cell‐Based HIV‐1 Therapeutic Vaccine Candidates | |
| US20240091343A1 (en) | Technology platform of uncapped-linear mrna with unmodified uridine | |
| WO2001030989A3 (en) | Method for creating divergent populations of nucleic acid molecules and proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |